WO2006030792A1 - 非アルコール性脂肪性肝炎病態モデル動物 - Google Patents
非アルコール性脂肪性肝炎病態モデル動物 Download PDFInfo
- Publication number
- WO2006030792A1 WO2006030792A1 PCT/JP2005/016854 JP2005016854W WO2006030792A1 WO 2006030792 A1 WO2006030792 A1 WO 2006030792A1 JP 2005016854 W JP2005016854 W JP 2005016854W WO 2006030792 A1 WO2006030792 A1 WO 2006030792A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- liver
- mice
- hfd
- mrna
- fat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
Definitions
- the present invention relates to a non-alcoholic steatohepatitis model animal, a method for producing the animal, and a drug screening method using the animal.
- non-alcoholic fatty liver (not caused by alcohol consumption, fatty liver) has been considered to be a condition that does not require any treatment that does not adversely affect the body.
- non-alcoholic fatty livers develop into hepatitis due to stimuli such as oxidative stress and further cause fibrosis of the liver, resulting in cirrhosis or liver cancer.
- NASH nonalcoholic steatohepatitis
- MCD model a mouse (hereinafter referred to as “MCD model”) produced by ingesting an MCD (methionine- and choline-deficient) diet is currently known.
- the MCD model is related to the development of steatohepatitis, increased alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the blood, and increased triglyceride (TG) in the liver! ], Characteristic findings of non-alcoholic steatohepatitis, such as increased mRNA of inflammatory site force in the liver (tumor necrosis factor a (TNF ⁇ ), interleukin 1 j8 (IL-1 j8), etc.) In view of this, it is considered an excellent non-alcoholic fatty hepatitis model animal!
- TNF ⁇ tumor necrosis factor a
- IL-1 j8 interleukin 1 j8
- Non-Patent Literature l Rinella, M. E. et al., J. Hepatology, 40: 47-51 (2004)
- the present invention overcomes the above-mentioned problems of the MCD model, and more accurately reflects the actual pathology of a patient with nonalcoholic steatohepatitis, a method for producing the same, and a nonalcoholic fat
- the purpose is to provide a more effective drug screening method for the development of therapeutic drugs for hepatitis.
- the present invention provides tetracycline antibiotics to animals whose body weight has been significantly increased by ingesting a high-fat diet compared to a group ingested a normal diet.
- a non-alcoholic steatohepatitis model animal produced by continuous administration.
- Such a non-alcoholic steatohepatitis model animal is a non-alcoholic steatohepatitis patient in that the body weight, blood insulin concentration and blood glucose concentration are normal values or higher. It becomes a disease state model animal that more accurately reflects the actual disease state.
- the high-fat diet is preferably a diet containing at least protein, carbohydrate and fat, and is preferably a diet having a fat-derived calorie occupying 30% or more of the total calories of the diet.
- Antibiotics should be administered continuously until blood ALT levels, blood AST levels, liver TG levels, liver TNF ⁇ mRNA levels, and liver IL lj8 mRNA levels are significantly higher than those of normal healthy animals. Good.
- the non-alcoholic steatohepatitis disease model animal is a high-fat diet that contains at least protein, carbohydrates and fat, and that contains at least 30% fat-derived calories in the total calories of the diet Blood ALT concentration, blood AST concentration, liver TG content, liver TNF a mRNA content and liver IL l j8 mRNA content strength are continuously ingested until it becomes significantly higher than that of healthy animals of the same species. Animals can also be employed. Such pathological model animals also have positive body weight, blood insulin concentration and blood glucose concentration. In terms of showing normal or higher values, it is a more accurate reflection of the actual condition of patients with nonalcoholic steatohepatitis. Depending on the intake period of the high-fat diet, it becomes a model animal with more advanced non-alcoholic steatohepatitis accompanied by fibrosis of the liver.
- a non-alcoholic steatohepatitis model animal is an animal whose body weight is significantly increased by feeding a high-fat diet compared to a group fed a normal diet. It can be prepared by continuously administering a tetracycline antibiotic.
- a high-fat diet is a diet that contains at least protein, carbohydrate, and fat, and a diet that contains at least 30% fat-derived calories in the total calories of the diet.
- Antibiotics should be administered continuously until blood ALT levels, blood AST levels, liver TG levels, liver TNF ⁇ mRNA levels, and liver IL lj8 mRNA levels are significantly higher than those of normal healthy animals. Prefer U ,.
- a disease model animal that overcomes the problems of the MCD model and more accurately reflects the actual disease state of a non-alcoholic steatohepatitis patient, a method for producing the disease model animal, and a non-alcoholic fat It is possible to provide a more effective drug screening method for the development of therapeutic drugs for hepatitis.
- FIG. 1 is a line graph showing the change in body weight in mice fed with HFD or a control diet for 8 weeks and intraperitoneally administered tetracycline hydrochloride for 10 days.
- FIG. 2 is a bar graph showing the plasma ALT concentration of mice that received HFD or a control diet for 8 weeks and intraperitoneally administered tetracycline hydrochloride for 10 days.
- FIG. 3 is a bar graph showing the plasma AST concentration of mice fed with HFD or a control diet for 8 weeks and intraperitoneally administered tetracycline hydrochloride for 10 days.
- FIG. 4 is a bar graph showing the plasma insulin concentration of mice that received HFD or a control diet for 8 weeks and were intraperitoneally administered with tetracycline hydrochloride for 10 days.
- FIG. 5 is a bar graph showing plasma glucose concentration of mice fed with HFD or a control diet for 8 weeks and intraperitoneally administered tetracycline hydrochloride for 10 days.
- [8] A bar graph showing the amount of liver IL 1 j8 mRNA in mice in which tetracycline hydrochloride was intraperitoneally administered for 10 days after ingesting HFD or control food for 8 weeks.
- FIG. 9 is a diagram corresponding to an optical micrograph showing the results of hematoxylin 'eosin staining on a section of a liver intermediate lobe of a mouse administered with HFD for 8 weeks and intraperitoneally administered tetracycline hydrochloride 30 mg ZkgZ for 10 days.
- FIG. 10 is a diagram corresponding to an optical micrograph in which a portion indicated by a black frame in FIG. 9 is enlarged.
- FIG. 11 is a diagram corresponding to a photomicrograph showing the result of oil red O staining of a section of a liver intermediate lobe of a mouse that was fed with HFD for 8 weeks and intraperitoneally administered tetracycline hydrochloride 30 mg ZkgZ for 10 days.
- FIG. 12 is a line graph showing the change in body weight of mice fed with HFD for 8 weeks and subcutaneously administered tetracycline hydrochloride for 10 days.
- FIG. 13 is a bar graph showing the plasma ALT concentration in mice that were ingested with HFD for 8 weeks and subcutaneously administered tetracycline hydrochloride for 10 days.
- FIG. 14 is a bar graph showing the plasma AST concentration in mice in which HFD was ingested for 8 weeks and tetracycline hydrochloride was administered subcutaneously for 10 days.
- FIG. 15 is a bar graph showing plasma insulin concentrations in mice administered with HFD for 8 weeks and subcutaneously administered tetracycline hydrochloride for 10 days.
- FIG. 16 is a bar graph showing the plasma glucose concentration of mice fed with HFD for 8 weeks and subcutaneously administered tetracycline hydrochloride for 10 days.
- FIG. 17 is a bar graph showing the amount of liver TG in mice fed with HFD for 8 weeks and subcutaneously administered tetracycline hydrochloride for 10 days.
- FIG. 18 is a bar graph showing the amount of liver TNF a mRNA in mice fed with HFD for 8 weeks and subcutaneously administered tetracycline hydrochloride for 10 days.
- FIG. 19 is a bar graph showing the amount of liver IL-1
- FIG. 20 is a bar graph showing the body weight of mice fed with HFD or control food for 50 weeks.
- FIG. 21 is a bar graph showing the plasma ALT concentration of mice fed with HFD or control food for 50 weeks.
- FIG. 22 is a bar graph showing plasma AST concentration in mice fed with HFD or control food for 50 weeks.
- FIG. 23 is a bar graph showing plasma insulin concentrations in mice fed with HFD or control diet for 50 weeks.
- FIG. 24 is a bar graph showing plasma glucose concentration of mice fed with HFD or control diet for 50 weeks.
- FIG. 25 is a bar graph showing the amount of liver TG in mice fed with HFD or control food for 50 weeks.
- FIG. 26 is a bar graph showing the amount of liver TNF a mRNA in mice fed with HFD or control food for 50 weeks.
- FIG. 27 is a bar graph showing the amount of liver IL-1
- FIG. 28 is a view corresponding to an optical micrograph showing the result of staining with hematoxylin and eosin on a section of the liver middle lobe of a mouse fed with HFD for 50 weeks.
- FIG. 29 is a view corresponding to an optical micrograph showing the results of hematoxylin-eosin staining of a section of the liver middle lobe of a mouse fed with a control diet for 50 weeks.
- FIG. 30 is a bar graph showing the amount of liver type I collagen DmRNA in mice fed with HFD or control food for 50 weeks.
- FIG. 31 is a bar graph showing the amount of liver ⁇ -SMA mRNA in mice fed with HFD or control food for 50 weeks.
- the animal used for producing the non-alcoholic steatohepatitis disease model animal of the present invention (hereinafter referred to as "NASH disease model animal") is generally used as a human disease disease model animal.
- the body weight is significantly increased as compared to the group fed with a normal diet.
- the high-fat food to be ingested should contain at least protein, carbohydrates and fat, and should have 30% or more of fat-derived calories in the total calories.
- the lower limit for calories from fat is preferably 45%, more preferably 60%.
- the upper limit is preferably 80%, more preferably 70%.
- the significance level in the t-test is 1% or 5%, preferably 1%.
- a NASH disease state model animal is produced by continuously administering tetracycline antibiotics to an animal whose body weight has significantly increased as described above.
- continuous administration means that administration is performed a plurality of times, preferably at regular intervals.
- tetracycline antibiotics administered continuously include tetracycline (TC), oxytetracycline (OTC), metacycline (MTC), doxycycline (DOXY), minocycline (MIN O), and salts thereof. (Hydrochloride, etc.).
- Tetracycline antibiotic administration significantly increases blood ALT concentration, blood AST concentration, liver TG level, liver TNF a mRNA level, and liver IL lj8 mRNA level compared to healthy animals of the same species.
- blood ALT concentration, blood AST concentration, liver TG amount, liver TNF a mRNA amount and liver IL l j8 mRNA amount are significantly higher than those of healthy animals of the same type, It is more preferable to continue until the presence of fatty liver and infiltration of inflammatory cells are observed in the histopathological examination of the liver.
- whether or not the above values are significantly higher than that of healthy animals of the same species can be determined by a t-test with a significance level of 1% or 5% (preferably 1%).
- a diet containing at least protein, carbohydrate, and fat, and a high-fat diet with a fat-derived calorie occupying 30% or more of the total calories of the diet, blood ALT Concentration, blood AST concentration, liver TG level, liver TNF a mRNA level and liver IL 1 mRNA level can be taken continuously for a certain period of time until they are significantly higher than those of healthy animals of the same species.
- NASH disease model animals can be produced without continuous administration of tetracycline antibiotics.
- continuous ingesting means ingesting multiple times.
- fatty liver is formed during the high fat diet intake period prior to tetracycline antibiotic administration.
- fatty liver is formed during the high fat diet intake period prior to tetracycline antibiotic administration.
- it is preferably 6 to 10 weeks, and more preferably 7 to 9 weeks. It is preferable to take a high-fat diet even during administration of tetracycline antibiotics.
- the dosage and administration period of the tetracycline antibiotic is preferably 20 to 20 for mice. : LOOmg / kg / day, 7 to 14 days, more preferably 20 to 40 mg ZkgZ day, 9 to: L 1 day. Fat liver may not develop hepatitis at 20 mg / kg / day for less than 7 days.On the other hand, if it exceeds lOOmgZkgZ day for 15 days, any of body weight, blood insulin concentration and blood glucose concentration is normal. May be lower than the value.
- the administration method of the tetracycline antibiotic is preferably intraperitoneal administration or subcutaneous administration.
- the tetracycline antibiotic may be administered in the form of a pharmacologically acceptable salt.
- the intake period of the high fat diet should be sufficient to develop steatohepatitis.
- it is 20 weeks or more, more preferably 40 weeks or more. In less than 20 weeks, steatohepatitis may not fully develop.
- mice be fed a high-fat diet for 40 weeks or longer.
- the occurrence of liver fibrosis is, for example, that the amount of liver type I collagen (a 1) mRNA or liver a-SMA (smooth muscle actin) mRNA is significantly higher than that of healthy animals of the same species. Can be confirmed.
- type I collagen ( ⁇ 1) represents one chain of type I collagen.
- a screening method for a drug for non-alcoholic steatohepatitis comprising the step of administering a candidate drug for non-alcoholic steatohepatitis to a NASH disease model animal is provided.
- a step of determining whether the candidate drug is effective as a drug for nonalcoholic steatohepatitis can be provided after the step of administering the candidate drug.
- blood ALT Concentration, blood AST concentration, liver TG level, liver TNF o; mRNA level and liver IL-1 ⁇ mRNA level are not significantly higher than those of healthy animals of the same type.
- the effectiveness as a drug can be determined.
- the effectiveness as a drug for non-alcoholic steatohepatitis can be determined based on the absence of inflammatory cell infiltration in the histopathological examination of the liver.
- NASH disease model animal of the present invention and the drug screening method using the same are the same as the known disease model animal and the drug screening method using the same in screening tests and pharmacological tests for the purpose of drug development. Can be used.
- C57B LZ6J male mice (CLEA Japan, Inc.) were used as animals for preparing pathological model animals.
- HFD high fat diet
- D12492 fat content: 60 kcal%) (Research Diet) was used.
- CE-2 (CLEA Japan) used for normal breeding of mice was used.
- Tetracycline hydrochloride tetracycline hydrochloride (Sigma) was used as a tetracycline antibiotic.
- Tetracycline hydrochloride was administered by injection of 0, 10, 30 and lOOmg / lOmL solutions of tetracycline hydrochloride prepared with 0.5% saline.
- “OmgZlOmL solution of tetracytalin hydrochloride” means 0.5% physiological saline.
- HFD group 15 groups that received HFD
- control group 14 groups that received control food
- mice in the HFD group and the control group were allowed to freely ingest HFD and control food for 8 weeks, respectively.
- the HFD group was divided into 3 groups (5 animals x 3) and the control group was divided into 3 groups (5 animals x 2, 4 animals x 1) so that the body weight and body fat percentage were equal among the groups.
- the groups and control groups were given intraperitoneal administration of tetracycline hydrochloride 0, 10 and 30 mg ZkgZ for 10 days (hereinafter referred to as ⁇ TCO group '' and ⁇ TCIO Group "and" TC30 group ").
- HFD or control food was given to mice ad libitum during the tetracycline hydrochloride administration period.
- FIG. 1 is a line graph showing the change in body weight in mice fed with HFD or control diet for 8 weeks and intraperitoneally administered tetracycline hydrochloride for 10 days. From Fig. 1, the body weight of the HFD group mice was significantly higher than that of normal mice (TC0 group mice in the control group) at the start of tetracycline hydrochloride administration, and this value was almost maintained during the administration period. You can see that In FIG. 1, “days” represents the number of days that have elapsed since the start of tetracycline hydrochloride administration.
- mice On the day after the end of tetracycline hydrochloride administration (11 days after the start of administration), the mice were inhaled with isoflurane and anesthetized. Blood was collected with a syringe containing henon. The collected blood was centrifuged at 4 ° C and 75 OOrpm for 10 minutes to separate plasma. The obtained plasma was stored frozen. After blood collection, the thorax was dissected quickly and forcefully to release blood, and then the liver was removed. One liver leaf was stored frozen. A part of the liver (about 50 mg) was excised and stored frozen in liquid nitrogen. Furthermore, the intermediate lobe of the liver was fixed with 10% neutral buffered formalin solution.
- FIG. 2 is a bar graph showing the plasma ALT concentration of mice that received HFD or control food for 8 weeks and intraperitoneally administered tetracycline hydrochloride for 10 days.
- FIG. 3 is a bar graph showing the plasma AST concentration of mice that received HFD or control food for 8 weeks and intraperitoneally administered tetracycline hydrochloride for 10 days.
- FIG. 4 is a bar graph showing the plasma insulin concentration of mice that received HFD or control food for 8 weeks and intraperitoneally administered tetracycline hydrochloride for 10 days.
- FIG. 5 is a bar graph showing the plasma glucose concentration in mice fed with HFD or control diet for 8 weeks and intraperitoneally administered tetracycline hydrochloride for 10 days. 4 and 5, it can be seen that in the plasma insulin concentration and plasma glucose concentration, the mice in the HFD group showed the same or higher values than the normal mice.
- FIG. 6 is a bar graph showing the amount of liver TG in mice fed with HFD or control diet for 8 weeks and intraperitoneally administered tetracycline hydrochloride for 10 days.
- FIG. 6 shows that the amount of liver TG was significantly higher in the HFD group of mice than in the normal mouse, and in particular, the TC30 group of mice was significantly higher.
- liver TNF a mRNA level and liver IL 1 j8 mRNA level are measured by measuring liver TNF a mRNA level and liver IL 1 j8 mRNA level.
- FIG. 7 is a bar graph showing the amount of liver TNF a mRNA in mice fed with HFD or control diet for 8 weeks and intraperitoneally administered tetracycline hydrochloride for 10 days.
- liver TN liver TN It can be seen that in the amount of Fa mRNA and the amount of liver IL lj8 mRNA, the mice in the TC10 group and the TC30 group in the HFD group showed significantly higher values than the normal mice.
- FIG. 9 is a diagram corresponding to an optical micrograph showing the result of hematoxylin 'eosin staining of a section of the liver intermediate lobe of a mouse that was ingested with HFD for 8 weeks and intraperitoneally administered 30 mgZkgZ day of tetracycline hydrochloride for 10 days.
- FIG. 10 is a diagram corresponding to an optical micrograph in which the portion indicated by the black frame in FIG. 9 is enlarged.
- FIG. 11 is a diagram corresponding to an optical micrograph showing the result of oil red O staining of a section of a liver mesenchyme of a mouse that was ingested with HFD for 8 weeks and intraperitoneally administered tetracycline hydrochloride 30 mgZkgZ for 10 days.
- Fig. 9 ⁇ From L1, it can be seen that the presence of fatty liver and infiltration of inflammatory cells were observed in mice in the TC30 group in the HFD group.
- mice were ingested with a high fat diet for 8 weeks, followed by intraperitoneal administration of tetracycline hydrochloride 30mgZkgZ for 10 days, so that body weight, blood insulin concentration and blood It was shown that NASH pathological model animals showing normal or higher glucose concentrations were produced.
- mice Twenty mice (7 weeks old) were allowed free intake of HFD for 8 weeks. After that, it was divided into 4 groups (5 animals x 4) so that the body weight and body fat percentage were equal among the groups, and tetracycline hydrochloride 0, 30, 60 and 100 mg / kg / day were administered subcutaneously for 10 days (hereinafter referred to as hydrochloric acid).
- the groups that received tetracycline 0, 30, 60, and lOOmgZkgZ day were referred to as “TC0 group”, “TC30 group”, “TC60 group”, and “TC100 group”, respectively).
- HFD was freely taken by mice even during the administration of tetracycline hydrochloride.
- mice The body weight of the mice was measured 3 days before the start of tetracycline hydrochloride administration, and further measured every day from the next day to the 11th day.
- Figure 12 shows tetrassa hydrochloride ingested HFD for 8 weeks.
- 2 is a line graph showing changes in body weight in mice administered with iclin subcutaneously for 10 days. From FIG. 12, all the groups of mice showed significantly higher values than normal mice at the start of tetracycline hydrochloride administration, and the body weight decreased according to the dose of tetracycline hydrochloride and the number of administration days. It can be seen that these mice showed the same strength and higher values as normal mice at the end of tetracycline hydrochloride administration (see Fig. 1). In FIG. 12, “days” represents the number of days that have elapsed since the start of tetracycline hydrochloride administration.
- FIG. 13 is a bar graph showing the plasma ALT concentration of mice administered with HFD for 8 weeks and subcutaneously administered with tetracycline hydrochloride for 10 days.
- FIG. 14 is a bar graph showing plasma AST concentrations in mice that received HFD for 8 weeks and subcutaneously administered tetracycline hydrochloride for 10 days. 13 and 14, it can be seen that in the plasma ALT concentration and plasma AST concentration, mice in the TC30 group, TC60 group and TC100 group showed significantly higher values than normal mice (see FIGS. 2 and 3).
- FIG. 13 is a bar graph showing the plasma ALT concentration of mice administered with HFD for 8 weeks and subcutaneously administered with tetracycline hydrochloride for 10 days.
- FIG. 15 is a bar graph showing plasma insulin concentrations in mice administered with HFD for 8 weeks and subcutaneously administered tetracycline hydrochloride for 10 days. From Fig. 15, it can be seen that in the plasma insulin concentration, mice in the TCO group, TC30 group and TC60 group showed higher values than normal mice, and mice in the TC100 group showed similar values to normal mice (Fig. 15). 4).
- FIG. 16 is a bar graph showing the plasma glucose concentration of mice fed with HFD for 8 weeks and subcutaneously administered tetracycline hydrochloride for 10 days. From Fig. 16, it can be seen that the plasma glucose concentration of each group of mice was higher than that of normal mice (see Fig. 5).
- FIG. 17 is a bar graph showing the amount of liver TG in mice fed with HFD for 8 weeks and subcutaneously administered tetracycline hydrochloride for 10 days. From Fig. 17, the liver TG level was significantly higher in all groups of mice than in normal mice. However, it can be seen that the TC30 group of mice showed extremely high values (see Fig. 6).
- liver TNF a mRNA level and liver IL 1 j8 mRNA level are measured by measuring liver TNF a mRNA level and liver IL 1 j8 mRNA level.
- FIG. 18 is a bar graph showing the amount of liver TNF a mRNA in mice in which HFD was ingested for 8 weeks and tetracycline hydrochloride was administered subcutaneously for 10 days.
- FIG. 19 is a bar graph showing the amount of liver IL-1 ⁇ mRNA in mice fed with HFD for 8 weeks and subcutaneously administered tetracycline hydrochloride for 10 days.
- Figures 18 and 19 show that mice with TC30, TC60 and TC100 showed significantly higher levels of liver TNF a mRNA and liver IL 1 j8 mRNA than normal mice, including TC30 mice. However, the amount of mRNA in the gap is extremely high! ⁇ ⁇ ⁇ It can be seen that the values were shown (see Figures 7 and 8).
- the histopathological examination of the liver was carried out in the same manner as in Example 1. Presence of fatty liver and infiltration of inflammatory cells were observed in the mice of TC30 group, TC60 group and TC100 group.
- mice were ingested with a high fat diet for 8 weeks, and tetracycline hydrochloride was administered subcutaneously for 10 days, so that body weight, blood insulin concentration and blood glucose concentration were normal or higher. It was shown that NASH pathological model animals exhibiting values were produced.
- Example 3 Twelve mice (7 weeks old) were divided into 6 HFD groups and 6 control groups.
- the following experiments on the HFD group (6 animals) and the control group (6 animals) are referred to as Example 3 and Comparative Example 2, respectively.
- mice in the HFD group and the control group were allowed to freely take HFD and control food for 50 weeks, respectively.
- FIG. 20 is a bar graph showing the body weight of mice fed HFD or control diet for 50 weeks. From Fig. 20, it can be concluded that the mice in the HFD group showed significantly higher values than normal mice in terms of body weight (see Fig. 1). [0048] Blood collection and dissection:
- FIG. 21 is a bar graph showing plasma ALT concentrations in mice fed with HFD or control diet for 50 weeks.
- FIG. 22 is a bar graph showing plasma AST concentrations in mice fed HFD or control diet for 50 weeks. 21 and 22, it can be seen that the plasma ALT concentration and the plasma AST concentration were significantly higher in the HFD group than in the normal mouse (see FIGS. 2 and 3).
- FIG. 23 is a bar graph showing plasma insulin concentrations in mice fed with HFD or control diet for 50 weeks. From FIG. 23, it can be seen that the plasma insulin concentration was higher in the HFD group of mice than in the normal mice (see FIG. 4).
- Figure 24 is a bar graph showing plasma glucose concentrations in mice fed with HFD or control diet for 50 weeks. From FIG. 24, it can be seen that in the plasma glucose concentration, the mice in the HFD group showed similar values to the normal mice (see FIG. 5).
- FIG. 25 is a bar graph showing the amount of liver TG in mice fed with HFD or control food for 50 weeks.
- FIG. 25 shows that the amount of liver TG was significantly higher in the HFD group of mice than in normal mice (see FIG. 6).
- liver TNF a mRNA level and liver IL 1 j8 mRNA level Measurement of liver TNF a mRNA level and liver IL 1 j8 mRNA level:
- FIG. 26 is a bar graph showing the amount of liver TNF a mRNA in mice fed with HFD or control diet for 50 weeks.
- FIG. 27 is a bar graph showing the amount of liver IL- ⁇ mRNA in mice fed with HFD or control diet for 50 weeks. 26 and 27, it can be seen that the liver TNF a mRNA level and the liver IL 1 j8 mRNA level were significantly higher in the HFD group of mice than in the normal mice (see FIGS. 7 and 8).
- FIG. 28 is a diagram corresponding to an optical micrograph showing the results of hematoxylin and eosin staining of a section of the liver intermediate lobe of a mouse fed with HFD for 50 weeks.
- FIG. 29 is a diagram corresponding to an optical micrograph showing the result of staining with hematoxylin 'eosin on a section of a liver intermediate lobe of a mouse fed with a control diet for 50 weeks. From FIGS. 28 and 29, it can be seen that the presence of fatty liver and infiltration of inflammatory cells were observed in mice in the HFD group.
- liver type I collagen ⁇ 1 mRNA level and liver ⁇ -SMA mRNA level:
- liver fibrosis occurred was confirmed by using liver type I collagen ( ⁇ 1) mRNA level and liver ex-SMA mRNA level as indicators.
- FIG. 30 is a bar graph showing the amount of liver type I collagen 1) mRNA in mice fed with HFD or control diet for 50 weeks.
- FIG. 31 is a bar graph showing the amount of liver ⁇ -SMA mRNA in mice fed with HFD or control food for 50 weeks.
- mice were allowed to ingest a high fat diet for 50 weeks, whereby body weight, blood insulin concentration and blood glucose concentration showed normal values or higher values, and It has been shown that NASH pathological model animals can be produced in which fibrosis occurs.
- the present invention can be used for the development of a drug for non-alcoholic steatohepatitis.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002580669A CA2580669A1 (en) | 2004-09-17 | 2005-09-13 | Pathologic model animal for nonalcoholic steatohepatitis |
US11/663,155 US20080118436A1 (en) | 2004-09-17 | 2005-09-13 | Pathological Animal Model For Non-Alcoholic Fatty Hepatitis |
JP2006535155A JPWO2006030792A1 (ja) | 2004-09-17 | 2005-09-13 | 非アルコール性脂肪性肝炎病態モデル動物 |
EP05783443A EP1790220A4 (en) | 2004-09-17 | 2005-09-13 | ANIMAL DISEASE MODEL FOR NON-ALCOHOLIC GREASE HEPATITIS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004272313 | 2004-09-17 | ||
JP2004-272313 | 2004-09-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006030792A1 true WO2006030792A1 (ja) | 2006-03-23 |
Family
ID=36060043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/016854 WO2006030792A1 (ja) | 2004-09-17 | 2005-09-13 | 非アルコール性脂肪性肝炎病態モデル動物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080118436A1 (ja) |
EP (1) | EP1790220A4 (ja) |
JP (1) | JPWO2006030792A1 (ja) |
CA (1) | CA2580669A1 (ja) |
WO (1) | WO2006030792A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008018191A1 (fr) * | 2006-08-10 | 2008-02-14 | National University Corporation Okayama University | Animal expérimental en tant que modèle pathologique, procédé de production de l'animal expérimental, et procédé d'utilisation dudit animal expérimental |
WO2013015331A1 (ja) * | 2011-07-25 | 2013-01-31 | 株式会社ヤクルト本社 | Nashモデル動物 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102792919B (zh) * | 2012-08-08 | 2015-09-09 | 上海交通大学 | 悉生动物肥胖模型的构建方法及其应用 |
RU2598351C1 (ru) * | 2015-05-25 | 2016-09-20 | Государственное образовательное учреждение высшего профессионального образования Московский государственный областной университет | Способ моделирования неалкогольного стеатогепатита у крыс |
CN106666171A (zh) * | 2016-12-27 | 2017-05-17 | 李敬东 | 小鼠肥胖与酒精协同增效性肝病全胃营养液 |
-
2005
- 2005-09-13 WO PCT/JP2005/016854 patent/WO2006030792A1/ja active Application Filing
- 2005-09-13 CA CA002580669A patent/CA2580669A1/en not_active Abandoned
- 2005-09-13 JP JP2006535155A patent/JPWO2006030792A1/ja not_active Withdrawn
- 2005-09-13 US US11/663,155 patent/US20080118436A1/en not_active Abandoned
- 2005-09-13 EP EP05783443A patent/EP1790220A4/en not_active Withdrawn
Non-Patent Citations (4)
Title |
---|
FAN JG ET AL: "7 preventive effects of metformin on rats with nonalcoholic steatohepatitis.", vol. 38, no. 4, 2003, pages 501A, XP004623926 * |
LIEBER CS ET AL: "Acarbose attenuates experimental non-alcoholic steatohepatitis.", BIOCHEM BIOPHYS RES COMMUN., vol. 315, no. 3, 12 March 2004 (2004-03-12), pages 699 - 703, XP004490120 * |
LIEBER CS ET AL: "Model of nonalcoholic steatohepatitis.", AM J CLIN NUTR., vol. 79, no. 3, May 2004 (2004-05-01), pages 502 - 509, XP002994368 * |
See also references of EP1790220A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008018191A1 (fr) * | 2006-08-10 | 2008-02-14 | National University Corporation Okayama University | Animal expérimental en tant que modèle pathologique, procédé de production de l'animal expérimental, et procédé d'utilisation dudit animal expérimental |
US20100189647A1 (en) * | 2006-08-10 | 2010-07-29 | Fusako Takayama | Experimental Animal As Pathological Model, Method of Producing the Experimental Animal, and Method of Using the Experimental Animal |
WO2013015331A1 (ja) * | 2011-07-25 | 2013-01-31 | 株式会社ヤクルト本社 | Nashモデル動物 |
Also Published As
Publication number | Publication date |
---|---|
CA2580669A1 (en) | 2006-03-23 |
EP1790220A4 (en) | 2008-04-30 |
US20080118436A1 (en) | 2008-05-22 |
EP1790220A1 (en) | 2007-05-30 |
JPWO2006030792A1 (ja) | 2008-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10772865B2 (en) | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy | |
Sanyal et al. | A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis | |
RU2743075C2 (ru) | Способы применения агонистов fxr | |
Wang et al. | Plasma cholesteryl ester transfer protein is predominantly derived from Kupffer cells | |
CN110200981A (zh) | 五环三萜皂苷的医药用途及其药物组合物 | |
AU2024200737A1 (en) | Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash) | |
KR20170049606A (ko) | 간 질환을 치료하기 위한 오메가-3 지방산과 sglt-2 억제제의 조합 | |
Wu et al. | Mesenteric adipose tissue contributes to intestinal barrier integrity and protects against nonalcoholic fatty liver disease in mice | |
KR102218498B1 (ko) | Fxr 작용제들의 조합물 | |
CN106659722A (zh) | 用于预防或治疗脂肪肝疾病的组合物 | |
WO2006030792A1 (ja) | 非アルコール性脂肪性肝炎病態モデル動物 | |
CN112274523A (zh) | 一种治疗脂肪肝的药物和治疗方法 | |
JP2019530696A (ja) | 線維性、硬変性の疾患もしくは障害を治療または予防するためのfxrアゴニストを含む組合せ組成物 | |
CN113730422A (zh) | 白头翁皂苷b4在制备预防或者治疗非酒精性脂肪肝的药物中的应用 | |
TWI631943B (zh) | 治療脂肪肝疾病之方法 | |
KR20190044667A (ko) | Fxr 작용제의 신규 요법 | |
CN113424795B (zh) | 一种急性胰腺炎动物模型的构建方法和用途 | |
US20220193102A1 (en) | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) | |
Al-Araimi et al. | Gum Arabic Supplementation Suppresses Colonic Fibrosis After Acute Colitis by Reducing Transforming Growth Factor β 1 Expression | |
CN113368107B (zh) | 包含小檗碱和苦参碱的药物组合物及其治疗或预防非酒精性脂肪性肝病的用途 | |
CN110917186A (zh) | 淫羊藿素在制备治疗支气管哮喘药物中的应用 | |
Abdurahmanov et al. | Does vitamin D replacement therapy cause a regression in fatty liver disease? A case control study of comparison of vitamin D and other common therapy modalities | |
US20220193065A1 (en) | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) | |
CN117883574A (zh) | 苹果酸酶1抑制剂在制备治疗肺纤维化药物中的应用 | |
KR20210027169A (ko) | 비알콜성 지방간염(NASH, Nonalcoholic Steatohepatitis) 치료 또는 예방을 위한 약학 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005783443 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006535155 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11663155 Country of ref document: US Ref document number: 2580669 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005783443 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11663155 Country of ref document: US |